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Malaria is a real and constant danger to nearly half of the world’s population of 7.4 billion 
people. In 2015, 212 million cases were reported along with 429,000 estimated deaths. 
The World Health Organization recommends artemisinin-based combinatorial therapies, 
and the artemisinin for this purpose is mainly isolated from the plant Artemisia annua. 
However, the plant supply of artemisinin is irregular, leading to fluctuation in prices. Here, 
we report the development of a simple, sustainable, and scalable production platform of 
artemisinin. The five genes involved in artemisinin biosynthesis were engineered into the 
moss Physcomitrella patens via direct in vivo assembly of multiple DNA fragments. In vivo 
biosynthesis of artemisinin was obtained without further modifications. A high initial pro-
duction of 0.21 mg/g dry weight artemisinin was observed after only 3 days of cultivation. 
Our study shows that P. patens can be a sustainable and efficient production platform 
of artemisinin that without further modifications allow for industrial-scale production. 
A stable supply of artemisinin will lower the price of artemisinin-based treatments, hence 
become more affordable to the lower income communities most affected by malaria; an 
important step toward containment of this deadly disease threatening millions every year.
Keywords: Physcomitrella patens, malaria, artemisinin, in vivo assembly, bioengineering
inTrODUcTiOn
Physcomitrella patens is a non-vascular plant that has been well established as a model organism 
to be used in basic research and in applied biotechnology (Simonsen et al., 2009; Buttner-Mainik 
et al., 2011; Ikram et al., 2015; Reski et al., 2015). The genome is fully sequenced and the haploid life 
cycle and efficient homologous recombination makes P. patens an attractive industrial production 
system compared to other plant hosts (Schaefer and Zrÿd, 1997; Reski, 1998). Additionally, a novel 
transformation technology involving in vivo assembly of multiple DNA fragments in P. patens has 
been established, further increasing the potential as a photosynthetic chassis for synthetic biology 
(King et al., 2016). Currently, several recombinant pharmaceutical proteins and molecules of com-
mercial value are being produced in this system (Anterola et al., 2009; Zhan et al., 2014; Pan et al., 
2015; Reski et al., 2015).
FigUre 1 | Schematic representation of the engineered artemisinin 
biosynthetic pathway in Physcomitrella patens. The five genes that encode 
the dihydroartemisinic acid biosynthetic pathway are ADS, amorphadiene 
synthase; CYP71AV1, amorphadiene oxidase; ADH1, alcohol dehydrogenase 
1; DBR2, artemisinic aldehyde double-bond reductase; ALDH1, aldehyde 
dehydrogenase 1. The numbers 1–3 indicates transformation sets.
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Artemisinin originates from the plant Artemisinia annua 
and is the first-choice treatment for malaria (Novotny et  al., 
1966). Chemically, artemisinin is a sesquiterpene lactone bear-
ing a unique endoperoxide structure and its complex structure 
makes it difficult and not economically feasible to be chemically 
synthesized (Pandey and Pandey-Rai, 2016). Several efforts have 
been made to obtain artemisinin from a stable source, such as 
yeast (Ro et  al., 2006), where a production of artemisinic acid 
followed by a three-step chemical synthesis to artemisinin was 
established (Paddon and Keasling, 2014). It was previously 
shown that artemisinin could be mass-produced by cultivation 
of A. annua or semi-synthetically in microorganisms producing 
artemisinic acid (Paddon and Keasling, 2014). Besides these 
efforts, extensive bioengineering of modified Nicotiana plants 
(Malhotra et al., 2016; Wang et al., 2016) has provided limited 
production of artemisinin. However, these have not yet been used 
for large-scale production. Currently, there are no reports on the 
stable heterologous biosynthesis of artemisinin in photosynthetic 
organisms that can be grown in bioreactors.
In order to produce artemisinin in P. patens, we introduced 
the five genes responsible for the biosynthesis of dihydroarte-
misinic acid (Figure 1), where amorpha-4,11-diene synthase, 
ADS (Komatsu et  al., 2010) catalyzes the first step. This was 
followed by the second step, the cytochrome P450, CYP71AV1 
(Ro et al., 2006) which we linked with the third step, the alcohol 
dehydrogenase 1 (ADH1) (Paddon et al., 2013) by the hybrid 
LP4/2A peptide linker (François et  al., 2004). Finally, we 
introduced the fourth step catalyzed by double-bond reductase 
2 (DBR2) (Zhang et  al., 2008) and the fifth step, being the 
aldehyde dehydrogenase 1 (ALDH1) (Teoh et al., 2009). These 
five genes would yield dihydroartemisinic acid. The final con-
version of dihydroartemisinic acid into artemisinin is thought 
to occur by photooxidation (Sy and Brown, 2002), thus the 
enzymatic end product is dihydroartemisinic acid. The five 
genes were transformed into P. patens using in  vivo homolo-
gous recombination that allows multiple DNA fragments to be 
transformed at once into the genome (King et al., 2016). Here, 
we show that engineered P. patens can produce significant levels 
of artemisinin. This could become a sustainable and efficient 
production platform of artemisinin, which could potentially 
help to stabilize the supply of artemisinin and aid in containing 
malaria.
MaTerials anD MeThODs
P. patens Material and growth conditions
Physcomitrella patens (Gransden ecotype, International Moss 
Stock Center #40001) was grown on solid and liquid PhyB 
media under sterile conditions, at 25°C with continuous 20–50 
W/m2 light intensity. For PhyB media mix 800  mg Ca(NO3)2, 
250 mg MgSO4⋅7H2O, 12.5 mg FeSO4⋅7H20, 0.5 g (NH4)2C4H4O, 
10  mL KH2PO4 buffer (25  g KH2PO4 per liter and adjusted to 
pH 6.5 with 4  M KOH), and 0.25  mL trace element solution 
(110  mg CuSO4⋅5H20, 110  mg ZnSO4⋅7H2O, 1,228  mg H3BO3, 
778  mg MnCl2⋅4H2O, 110  mg CoCl2⋅6H2O, 53  mg KI, 50  mg 
Na2MoO4⋅2H2O per liter). The medium can be solidified with 
0.7% (w/v) agar and is sterilized by autoclaving at 121°C (Bach 
et al., 2014).
Transformation of P. patens
A detailed description of P. patens transformation was 
previously published (Bach et  al., 2014). Five days cultured 
P. patens with approximately 1.5 g (fresh weight) was digested 
3Khairul Ikram et al. Stable Production of Artemisinin in Moss
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org August 2017 | Volume 5 | Article 47
by adding 1 mL of 0.5% DriselaseR enzyme solution in 8.5% 
mannitol (Sigma D9515) for every 40  mg of P. patens tissue. 
The tissue was incubated at room temperature with occasional 
gentle shaking for 30–60  min before filtering through a 
100-µm pored mesh-filter. The filtrate was collected by cen-
trifugation at 150–200 × g for 4 min with slow breaking. The 
pellet was washed twice with protoplast wash solution (8.5% 
mannitol, 10  mM CaCl2). Protoplast density was measured 
using a hemocytometer, and resuspended in MMM solution 
(9.1% d-mannitol, 10% MES, and 15 mM MgCl2) at a concen-
tration of 1.6 ×  106 protoplasts/mL. 300 µL of the protoplast 
suspension and 300 µL of PEG solution were added to a 15-mL 
tube containing 10  µg total DNA followed by incubation in 
a water bath for 5  min at 45°C and another 5  min at room 
temperature. 300 µL of 8.5% d-mannitol were added five times 
followed by another five times dilutions with 1  mL of 8.5% 
d-mannitol. Transformed protoplasts were pelleted by cen-
trifugation and resuspended in 500 µL of 8.5% d-mannitol and 
2.5  mL of protoplast regeneration media (top layer; PRMT). 
1 mL of the mixture was dispensed on three plates containing 
protoplast regeneration media (bottom layer; PRMB) overlaid 
with cellophane. The plates were incubated in continuous light 
for 5–7  days at 25°C. The cellophane and regenerating pro-
toplasts were then transferred to PhyB media containing the 
appropriate selection marker for 2 weeks, before transferring 
on PhyB media without antibiotics for another 2 weeks. This 
process was repeated twice, after which the stable transfor-
mants was kept on PhyB media with biweekly subcultivation 
including blending in sterile water until further use.
Dna Fragments and genes
The Pp108 locus homologous recombination flanking regions 
were amplified from P. patens genomic DNA. The ADS gene was 
a kind gift from Assoc. Prof. Dae Kyun Ro, University of Calgary, 
Canada. The synthetic genes CYP71AV1 (DQ268763), ADH1 
(JF910157.1), DBR2 (EU704257.1), and ALDH1 (FJ809784.1) 
were codon-optimized according to the P. patens codon usage 
by GenScript, USA. The Ubiquitin promoter and Ubiquitin 
terminator from Arabidopsis thaliana (CP002686.1) synthetic 
genes were also purchased from GenScript. The Maize Ubiquitin 
1 promoter and G418 selection cassettes were obtained from the 
pMP1355 vector, a kind gift from Prof. Mark Estelle, University 
of California San Diego, USA. The rice actin promoter and 
hygromycin selection cassette were obtained from the pZAG1 
vector, a kind gift from Assoc. Prof. Yuji Hiwatashi from Miyagi 
University, Japan.
Pcr, Dna Purification and concentration
The DNA fragments were amplified using PhusionR High-
Fidelity DNA Polymerase (New England Biolabs). The primers 
used are listed in Table S1 in Supplementary Material. PCR con-
ditions and annealing temperatures were modified depending 
on primers and templates used in the reaction. PCR reactions 
using plasmid DNA as template were digested with DpnI (NEB, 
USA) for 1 h at 37°C followed by inactivation at 65°C for 20 min 
to lower background after transformation. PCR products were 
purified using QIAquick PCR Purification Kit (QIAGEN GmbH, 
Germany). The DNA fragments for transformations were con-
centrated via ethanol precipitation to a final concentration of 
~1  μg/μL, determined using NanoDrop2000 (Thermo Fisher 
Scientific).
gc–Ms analysis of amorpha-4,11-Diene
Amorpha-4,11-diene production was measured using a 
Shimadzu GCMS-QP2010 Plus (GC-2010). The initial screen-
ing was performed by HS-SPME (Headspace-Solid Phase 
Micro-Extraction) (Drew et  al., 2012; Andersen et  al., 2015). 
Quantification of amorpha-4,11-diene was performed according 
to a published protocol (Rodriguez et al., 2014). One-week-old 
P. patens was blended in sterile water using a Polytron (PT 1200 
E, Kinematic AG) to a final concentration of 0.2  g/mL (fresh 
weight). Two milliliters of the blended P. patens were inoculated 
into 20 mL liquid PhyB media and cultivated on a shaker under 
standard conditions for 4 days. Then, 2 mL of decane were added 
into the P. patens culture and cultivation was continued for up 
to 2 weeks. After 2 weeks, 100 µL of decane was harvested and 
diluted twice in ethyl acetate spiked with an internal standard 
(trans-caryophyllene), and analyzed by GC–MS. 1  µL of the 
extract was injected in split mode and separated with HP-5MS 
UI column (20.0 m ×  0.18 mm ×  0.18 µm) with hydrogen as 
a carrier gas. The GC program was as follows, injection tem-
perature of 250°C, oven temperatures of 60°C for 3  min and 
60–320°C at 40°C/min. The amorpha-4,11-diene concentration 
was calculated based on the calibration curve of the internal 
standard run in parallel (Rodriguez et al., 2014).
P. patens growth and Biomass 
Measurements
Physcomitrella patens lines were blended in sterile water and 
subcultivated onto PhyB. After 1 week, the P. patens was blended 
for 30 s in sterile water, normalized to a concentration of 0.2 g/mL 
(fresh weight) as previously described (Zhan et al., 2014; Pan et al., 
2015). 2 mL of the blended P. patens was inoculated into 20 mL 
liquid PhyB media and cultivated on a horizontal shaker under 
standard conditions without aeration. The P. patens cultures were 
prepared in 3 replicates and harvested in 3, 6, 12, 15, and 18 days. 
The harvested P. patens tissue was dried overnight in an oven at 
90°C and weighed.
Metabolite extraction and UPlc-MrM-Ms 
analysis
Physcomitrella patens lines were blended in sterile water and 
subcultivated onto PhyB. After 1 week the fresh P. patens samples 
were harvested, snap-frozen, and ground into a fine powder. 
Samples of 3,000 mg were extracted with 3 mL citrate phosphate 
buffer, pH 5.4, followed by vortexing and sonication for 15 min. 
1  mL Viscozyme (Sigma V2010) was added and samples were 
incubated at 37°C. The whole mixture was then extracted three 
times with 3 mL ethyl acetate, concentrated to a volume of 1 mL, 
and stored at −20°C. For liquid culture extracts, 500 mL of liquid 
culture was harvested, passed through a filter paper and extracted 
with 200 mL of ethyl acetate in a separation funnel. Ethyl acetate 
was concentrated to a volume of 1 mL and stored at −20°C. Ethyl 
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acetate of both liquid culture and P. patens sample extracts were 
then dried under a flow of N2 and resuspended into 300 µL of 
75% MeOH:H2O (V:V). Extracts were passed through a 0.45-µm 
membrane filter (Minisart® RC4, Sartorius, Germany) before 
analysis.
Artemisinin and artemisinin biosynthesis pathway intermedi-
ates were measured in a targeted approach by using a Waters Xevo 
tandem quadrupole mass spectrometer equipped with an electro-
spray ionization source and coupled to an Acuity UPLC system 
(Waters), essentially as described before (Ting et  al., 2013). A 
BEH C18 column (100 mm × 2.1 mm × 1.7 µm; Waters) was used 
for chromatographic separation by applying a water:acetonitrile 
gradient. The gradient started with 5% (v/v) acetonitrile in 
water with formic acid [1:1,000 (v/v)] for 1.25 min, then raised 
to 50% in 2.35 min and further raised to 90% at 3.65 min. This 
was kept for 0.75  min before returning to the 5% acetonitrile/
water (v/v) with formic acid [1:1,000 (v/v)] by using a 0.15-min 
gradient. The same solvent composition was used to equilibrate 
the column for 1.85 min. The flow rate was 0.5 mL/min, and the 
column temperature was maintained at 50°C. Injection volume 
was set to 10 µL. Desolvation and cone gas flow were set to 1,000 
and 50 L/h, and the mass spectrometer was operated in positive 
ionization mode. Capillary voltage was set at 3.0 kV. Desolvation 
and source temperatures were set at 650 and 150°C, respectively. 
The cone voltage was optimized for all metabolites using the 
Waters IntelliStart MS Console. Fragmentation by collision-
induced dissociation was done in the ScanWave collision cell 
using argon. Multiple Reaction Monitoring (MRM) was used 
for detection and quantification of artemisinin. MRM transi-
tions for artemisinin and pathway intermediates measurement 
settings were optimized for MRM channels, which are presented 
in (Table S2 in Supplementary Material). Artemisinin and dihy-
droartemisinic acid were gifts from Dafra Pharma (Belgium). 
Other precursors were synthesized from dihydroartemisinic acid 
by Chiralix (Nijmegen, the Netherlands) and were then examined 
by NMR (>98% purity). External calibration curves were meas-
ured by using reference standards. The metabolite profiling was 
performed twice with 2  months apart, using the same original 
cell lines that had been subcultivated four times on PhyB media 
in between the analysis.
analysis of conjugated artemisinin 
Biosynthesis Pathway intermediates  
by lc-QTOF-Ms
In order to analyze the putative conjugated forms of artemisinin 
biosynthesis pathway intermediates, P. patens lines were blended 
in sterile water and subcultivated onto PhyB. After 1 week, 100 mg 
of fresh P. patens was ground in liquid nitrogen and extracted with 
300 µL MeOH:formic acid [1,000:1 (v/v)]. Samples were briefly 
vortexed and sonicated for 15 min, followed by 15 min centrifuga-
tion at 13,000 × g. Extracts were passed through a 0.45-µm mem-
brane filter (Minisart® RC4, Sartorius, Germany) before analysis 
on a Water alliance 2795 HPLC connected to a QTOF Ultima 
V 4.00.00 mass spectrometer (Waters. MS technologies, UK). 
The mass spectrometer was operated in negative ionization 
mode. A precoloumn of 2.0 mm × 4 mm (Phenomenex, USA) 
was connected to the C18 analytical column (Luna 3 µm C18/2 
100A; 2.0 mm × 150 mm; Phenomenex, USA). Degassed eluent 
A and B were HPLC-grade water:formic acid [1,000:1 (v/v)] and 
acetonitrile:formic acid [1,000:1 (v/v)], respectively. The flow rate 
was 19 mL/min. The HPLC gradient started from 5% eluent B and 
linearly increased to 75% in 45 min. after that the column was 
equilibrated for 15 min with 5% eluent B. 5 µL of each sample 
was used for injection.
P. patens cell components isolation  
and extraction
Physcomitrella patens protoplasts were isolated according to a 
previously published protocol (Bach et al., 2014). The P. patens 
lines were blended in sterile water and subcultivated onto PhyB. 
After 1 week, protoplast were isolated and pelleted by centrifuga-
tion at 150–200 × g for 4 min with slow breaking. Supernatant, 
which contained the apoplast (AP) was harvested and 10 mL of 
ultra-pure water was added to the pelleted protoplast to lyse the 
cells. Lysed cells were centrifuged at 6,000 × g for 10 min, and 
7  mL of the supernatant was mixed with an equal amount of 
sucrose to a final concentration of 0.3 M. The mixture was loaded 
into an ultracentrifuge tube with a 2 mL over-lay of water and 
centrifuged at 135,000 × g for 40 min at room temperature using 
a swinging bucket rotor. The bottom layers containing the cyto-
plasm (CT) and the cell pellet (CP) was harvested. The top layer 
(1.5 mL) containing neutral lipid bodies (LBs) was transferred to 
another centrifuge tube, mixed with sucrose to a final concentra-
tion of 0.3 M, overlaid with 2 mL of water as before, and 1 mL of 
the top-most layer of the LBs after centrifugation at 135,000 x g 
for 40 min. The harvested samples; AP, CT, LBs, and CP was then 
extracted with 3 mL ethyl acetate and concentrated to a volume 
of 1 mL and stored at −20°C. The samples were then dried under 
a flow of N2 and resuspended into 300  µL of 75% MeOH:H2O 
(V:V). Extracts were passed through a 0.45-µm membrane filter 
(Minisart® RC4, Sartorius, Germany) before analysis.
resUlTs anD DiscUssiOns
engineering of P. patens
We introduced ADS under the control of the strong constitutively 
expressed promoter, Ubiquitin1 from Zea mays with geneticin 
(G418) as resistance cassette. After two rounds of selection 
the ADS product amorpha-4,11-diene was detected in 11 lines 
with an average content of 200 mg/L, which is higher than in 
A. annua (Ma et al., 2009), Nicotiana tabacum (Wallaart et al., 
2001), E. coli (Martin et al., 2003), and yeast (Ro et al., 2006). 
An encouraging initial result was achieved without further 
optimization of terpenoid biosynthesis. The best producing line 
was selected for further transformation with CYP71AV1 and 
ADH1. The CYP71AV1-LP4/2A-ADH1 construct was controlled 
by the rice actin promoter with hygromycin resistance cassette. 
The genome homologous overhang was targeted to remove the 
previously integrated G418 cassette during the recombination 
event. Of 47 transformed lines, 11 were chemo- and genotyped 
and one line was selected for transformation with the final genes, 
DBR2 and ALDH1. The DBR2-LP4/2A-ALDH1 construct was 
FigUre 2 | UPLC-MRM-MS analysis of artemisinin produced from transgenic Physcomitrella patens, an internal standard (artemisinin) and WT as control with 
retention time. TIC represents the sum of multiple reaction monitoring channels used for the detection of artemisinin: m/z 283.19 > 219.21; 283.19 > 247.19; and 
283.19 > 265.22.
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controlled by the Arabidopsis Ubiquitin promoter and the G418 
selection cassette was used again. The hygromycin cassette was 
targeted for recombination to remove this selection marker. 
Three independent transformants were recovered, and genotyp-
ing showed that the five genes in the biosynthesis of dihydroar-
temisinic acid were integrated into the genome (Figure S1 in 
Supplementary Material). PCR analysis showed there was no 
untargeted integration for the selected lines. This showed that 
the selected P. patens lines have a uniform integration of the five 
genes and one copy of each.
Metabolite Profiling and growth  
of engineered strains
Extracts of the transgenic P. patens lines containing all five 
genes were analyzed using ultra-high performance liquid 
chromatography coupled with a triple quadrupole mass spec-
trometer operated in MRM mode (MRM) (UPLC-MRM-MS). 
MRM traces identical with the artemisinin standard were 
detected in the P. patens extracts, but not in the liquid culture 
medium or in extracts of wild-type P. patens (WT) (Figure 2; 
Figure S2 in Supplementary Material). The analysis was per-
formed twice with 2 months apart in triplicates each time. The 
presence of artemisinin, but no intermediates, in P. patens was 
confirmed by comparison with an artemisinin standard (Figure 
S2 in Supplementary Material). Quantification using external 
calibration showed that the artemisinin yield was 0.21 mg/g dry 
weight (DW), which is in the range of native A. annua (0.001–
1.54 mg/g DW) (Bhakuni et al., 2001) and in cross-bred plants 
(up to 10 mg/g DW) and higher in genetically engineered (up 
to 30 mg/g DW) (Tang et al., 2014). The amount of artemisinin 
in our P. patens lines is higher than what was initially obtained 
via heterologous expression in N. tabacum (0.0068 mg/g DW) 
(Farhi et al., 2011) and in Nicotiana benthamiana (0.003 mg/g 
DW) (Wang et  al., 2016). Recent efforts of targeting the bio-
synthesis to the chloroplast elevated the yield in N. tabacum 
to 0.8  mg/g DW (Malhotra et  al., 2016), since glycosylation 
of the precursors was avoided. Glycosylation and glutathione 
conjugation was previously shown to influence the yield in 
N. benthamiana (Mukanganyama et  al., 2001; van Herpen 
et al., 2010; Ting et al., 2013; Liu et al., 2014). We also explored 
the presence of sugar and glutathione conjugated products by 
liquid chromatography coupled to quadrupole time-of-flight 
mass spectrometry (LC-QTOF-MS). However, no glycosylated 
or glutathione conjugated products were detected in the culture 
medium nor in the P. patens extracts. The lack of glycosides 
may be explained by the fact that P. patens only has 20 glyco-
syltransferase 1 (GT1) genes that encode for enzymes involved 
in deactivation or detoxification of secondary metabolites, 
while higher vascular plants usually have hundreds (Yonekura-
Sakakibara and Hanada, 2011). As no pathway intermediates 
(conjugated or not) were detected in our extracts, we conclude 
that the pathway operates efficiently in P. patens.
A slight reduction in growth rate was observed after day 
12, resulting in 11% lower biomass in the transgenic line after 
18  days (Figure  3A). This indicates that there is just a small 
disruption of other metabolic pathways responsible for P. patens 
growth and fitness. The effect of artemisinin biosynthesis on 
P. patens growth is less, but follows and suggests the same pattern 
as was previously observed (Simonsen et al., 2009; Zhan et al., 
2014; Pan et al., 2015). The lesser growth is likely due to toxicity 
of the product and to depletion of nutrients in the media, but this 
FigUre 3 | Growth and production of artemisinin in Physcomitrella patens. (a) Time course analysis of growth of transgenic and WT P. patens in liquid culture. D0 
indicates the initial sub-culturing day. (B) Time course analysis of artemisinin production in P. patens. Error bars denote the SE of triplicate shake-flask liquid culture. 
(c) Production of artemisinin after 18 days of cultivation in different cellular component of AP, apoplast; CT, cytoplasm; LBs, lipid bodies; and CP, cell pellet.
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requires further studies in semi-continuous cultures. The highest 
concentration (0.21 mg/g DW) of artemisinin was observed after 
3 days of cultivation (Figure 3B), whereas the highest accumula-
tive amount of artemisinin (2.5 mg artemisinin) was observed at 
day 12. This is mainly due to the increase in biomass. This show 
that the primary production of artemisinin in P. patens happens 
within the first 2 weeks after subcultivation. This rapid produc-
tion of artemisinin is very valuable for future industrial produc-
tion and suggests that a semi-continuous batch cultivation with 
weekly extraction and disruption of the cells can provide high 
amounts of artemisinin.
Conversion of dihydroartemisinic acid to artemisinin in 
A. annua has been suggested to occur via photooxidation and 
induced by oxygen (Sy and Brown, 2002). In the present study, 
P. patens was grown under 24-h light and ambient air, which 
seems to facilitate the conversion to artemisinin as dihydroar-
temisinic acid was not detected in the extract. The reduction 
in artemisinin content from day 12 to day 18 might be due 
to chemical degradation of the compound, but no obvious 
breakdown products was found in the analysis; thus, this drop 
requires further studies.
storage of artemisinin in P. patens
Artemisinin biosynthesis occurs in the glandular trichomes of 
A. annua, but P. patens does not have trichomes. To identify 
the storage location of artemisinin in our transgenic P. patens, 
extracts of the AP, CT, LBs, and CPs were analyzed by UPLC-
MRM-MS. Artemisinin was detected in all the extracts except 
for the CPs (Figure 3C). The highest accumulation was in the 
AP at 0.04 mg/g DW (after 18 days of cultivation, analyzed at 
18 days to obtain enough biomass for the analysis) with 10- and 
20-fold less in the CT and LBs. In the native plant A. annua, 
dihydroartemisinic acid is transported to the subcuticular space 
of the glandular trichomes before photooxidation into arte-
misinin (Brown, 2010). The high accumulation of artemisinin 
in the P. patens AP indicates a transport of pathway products 
over the cell membrane, as also shown N. benthamiana (Wang 
et al., 2016).
This work demonstrates a stable production of artemisinin 
in a photosynthetic organism that allows for large-scale 
industrial production. The production will not be affected by 
environmental and ecological variables and overall have a lower 
environmental impact than field production (water usages, 
fertilizers, petrol usages, etc.). It should be noted that besides 
using codon-optimized sequences, no other enhancement, 
e.g. increasing terpenoid precursor supply or multi copy gene 
integration was applied. The high flux through the terpenoid 
pathway is likely to be due to the metabolic robustness of 
P. patens (Schaefer and Zrÿd, 1997). In contrast, yeast needed 
extensive and complex precursor pathway engineering prior to 
the introduction of the artemisinic acid pathway genes. Further 
optimization of the metabolic network in P. patens has been 
shown to optimize sesquiterpenoid production (Zhan et  al., 
2014) and possibly also artemisinin production. Possible targets 
include overexpression of the key enzymes, 3-hydroxy-3-meth-
ylglutaryl-CoA reductase (HMGR), and farnesyl diphosphate 
synthase (FPS), which improved terpenoid production in other 
plants (van Herpen et al., 2010) and microbial (Ro et al., 2006; 
Paddon et  al., 2013) hosts. Another possibility is targeting 
biosynthesis to different cellular compartments, which has also 
been shown to improve artemisinin and other sesquiterpenoid 
yield up to 1,000-fold in N. tabacum (Wu et al., 2006; Malhotra 
et al., 2016), which alone in P. patens would lead to a yield of 
210 mg/g DW.
Optimization of artemisinin yield in P. patens can poten-
tially result in a stable, sustainable, environmentally friendly, 
and commercially viable production platform. A considerable 
advantage of P. patens as an artemisinin production platform 
is that the extract only requires simple purification steps 
(Figure  2). This is different from the current yeast produc-
tion platform that requires further chemical synthesis to yield 
artemisinin (Paddon et al., 2013; Turconi et al., 2014) and the 
production in N. tabacum was only described as semi-pure 
extracts (Malhotra et al., 2016). The use of P. patens could lead 
to a reduced price for artemisinin-based treatments, allowing 
lower income communities most affected by malaria, to contain 
malaria. Furthermore, scaling up the production of artemisinin 
in plant-based bioreactors would expand the use of plant cells 
in bioreactors.
cOnclUsiOn
All five artemisinin biosynthetic pathway genes were engineered 
into the moss P. patens. In vivo biosynthesis of artemisinin was 
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obtained without further modifications and a high initial pro-
duction of 0.21 mg/g DW artemisinin was observed after only 
3 days of cultivation. This bioengineering achievement expands 
the frontiers of synthetic biotechnology, offering a genetically 
robust plant-based platform, which can be scaled up for industrial 
production of other complex high-value plant-based compounds. 
P. patens uses light as an energy source, thus is potentially more 
cost effective than other carbon supplemented biotechnological 
platforms.
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